TP53 and therapy-related myeloid neoplasm: Moreover, we wanted to compare in a cell-based model, after treatment with an alkylating agent (busulfan) or a topoisomerase II poison (doxorubicin), the differences between the two TP53 polymorphic variants concerning i) the number of DNA DSBs, measured by counting phosphorylated H2AX (γH2AX) foci25, ii) levels of DNA damage, measured as chromosome breaks or sister chromatid exchanges (SCEs), iii) the number of apoptotic cells, and finally iv) the development of chromosomal abnormalities typical of t-MN after a long term culture.